A Phase 3 interventional study of IPX066 95 mg and IPX066 145 mg in Parkinson's Disease, sponsored by Impax Laboratories, LLC. Completed at 81 sites in 10 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2019-11-08.
Sponsored by Impax Laboratories, LLC (part of Amneal Pharmaceuticals, Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. — 1 open to participants now, 1 under way, none of them phase 3. Parkinson Disease · Amneal Pharmaceuticals, Inc..
Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., this one is the 2nd largest by enrollment, is one of 2 that started in 2010, is one of 7 in phase 3, and was the 7th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →1 of the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. is open now, in 1 country. Recruiting first, the newest first:
Impax Laboratories, LLC · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 7 · Phase 4 1
First in 2005; this study’s year is marked. 2 started in 2010.
This study's enrollment of 617 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 77 across the 14 interventional studies. Of the 13 that completed or were terminated, 9 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Impax Laboratories, LLC, one of the names counted as Amneal Pharmaceuticals, Inc.. Under that name alone:
Impax Laboratories, LLC is the lead sponsor of 20 studies on the registry; 1 is open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 2 (25%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the long term safety and clinical utility of IPX066 in subjects with Parkinson's Disease.
IPX066 is intended for chronic treatment of motor symptoms for all stages of PD. This study is designed to enroll subjects who have successfully completed one of the following studies of IPX066:
All participants will be given IPX066 for 9 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Each subject must meet the following inclusion criteria in order to be enrolled in the study:
Exclusion Criteria:
Each subject must be free of the following exclusion criteria in order to be enrolled in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received IPX066 95 mg, IPX066 145 mg, IPX066 195 mg, or IPX066 245 mg for approximately 9 months. The dose and dosing frequency was determined by the investigator.
Drug: IPX066 95 mg · Drug: IPX066 145 mg · Drug: IPX066 195 mg · Drug: IPX066 245 mg
23.75 - 95 mg CD-LD capsules
Also known as: CD-LD ER 95 mg
36.25 - 145 mg CD-LD capsules
Also known as: CD-LD ER 145 mg
48.75 - 195 mg CD-LD capsules
Also known as: CD-LD ER195 mg
61.25 - 245 mg CD-LD capsules
Also known as: CD-LD ER 245 mg
Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III
Analysis of the Change from Baseline in the sum of the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living) + UPDRS Part III (Motor Examination) at End of Study. Unified Parkinson's Disease Rating Scale (UPDRS) - Four Parts Higher score values represent a worse outcome. Subscales II and III were summed: Part I: Mentation, Behavior and Mood - 4 questions 1-4 Score range: 1-16 Part II: Activities of Daily Living - 13 questions 5-17 Score range: 0-52 Part III: Motor Examination - 19 questions 18-31 and 25 total assessments Score range: 0-100 Part IV: Complications of Therapy (In the past week) - 11 questions Score range: 0-25
Time frame: 9 months
Total UPDRS Parts I-IV
Analysis of the Change from Baseline in the sum of the Unified Parkinson's Disease Rating Scale (UPDRS) Part I (Mentation, Behavior and Mood), Part II (Activities of Daily Living), UPDRS Part III (Motor Examination), and Part IV (Complications of Therapy \[In the past week\]) at End of Study. Includes both scoring by a clinician and a historical report of mental functioning, activities of daily living and complications of therapy in the past week obtained by questioning the patient. Unified Parkinson's Disease Rating Scale (UPDRS) - Four Parts Higher score values represent a worse outcome. Subscales II and III were summed: Part I: Mentation, Behavior and Mood - 4 questions 1-4 Score range: 1-16 Part II: Activities of Daily Living - 13 questions 5-17 Score range: 0-52 Part III: Motor Examination - 19 questions 18-31 and 25 total assessments Score range: 0-100 Part IV: Complications of Therapy (In the past week) - 11 questions Score range: 0-25
Time frame: 9 months
Patient Global Impression (PGI)
Satisfaction of IPX066 using Patient Global Impression (PGI) 7-point scale. Patient Global Impression 0-7 - higher value indicates increased improvement from study start
Time frame: 9 months
Study dates March 25, 2010 through October 19, 2011 Completion of previous trial a requirement
| Milestone | IPX066 |
|---|---|
| Started | 617 |
| Completed | 567 |
| Not completed | 50 |
| Withdrew: Adverse event | 16 |
| Withdrew: Death | 4 |
| Withdrew: Lack of efficacy | 4 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Withdrawal by subject | 22 |
| Withdrew: Physician decision | 1 |
| Withdrew: Noncompliance with study drug | 1 |
Analysis of the Change from Baseline in the sum of the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living) + UPDRS Part III (Motor Examination) at End of Study. Unified Parkinson's Disease Rating Scale (UPDRS) - Four Parts Higher score values represent a worse outcome. Subscales II and III were summed: Part I: Mentation, Behavior and Mood - 4 questions 1-4 Score range: 1-16 Part II: Activities of Daily Living - 13 questions 5-17 Score range: 0-52 Part III: Motor Examination - 19 questions 18-31 and 25 total assessments Score range: 0-100 Part IV: Complications of Therapy (In the past week) - 11 questions Score range: 0-25
| units on a scale | IPX066 |
|---|---|
| Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III | 26.4 ± 13.3 |
Analysis of the Change from Baseline in the sum of the Unified Parkinson's Disease Rating Scale (UPDRS) Part I (Mentation, Behavior and Mood), Part II (Activities of Daily Living), UPDRS Part III (Motor Examination), and Part IV (Complications of Therapy \[In the past week\]) at End of Study. Includes both scoring by a clinician and a historical report of mental functioning, activities of daily living and complications of therapy in the past week obtained by questioning the patient. Unified Parkinson's Disease Rating Scale (UPDRS) - Four Parts Higher score values represent a worse outcome. Subscales II and III were summed: Part I: Mentation, Behavior and Mood - 4 questions 1-4 Score range: 1-16 Part II: Activities of Daily Living - 13 questions 5-17 Score range: 0-52 Part III: Motor Examination - 19 questions 18-31 and 25 total assessments Score range: 0-100 Part IV: Complications of Therapy (In the past week) - 11 questions Score range: 0-25
| units on a scale | IPX066 |
|---|---|
| Total UPDRS Parts I-IV | 30.5 ± 14.67 |
Satisfaction of IPX066 using Patient Global Impression (PGI) 7-point scale. Patient Global Impression 0-7 - higher value indicates increased improvement from study start
| units on a scale | IPX066 |
|---|---|
| Patient Global Impression (PGI) | 5.4 ± 1.16 |
Collected over Screening through 9 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IPX066 | — | 43/617 (7%) | 122/617 (19.8%) |
| Event | IPX066 |
|---|---|
| Femoral neck fractureInjury, poisoning and procedural complications | 3/617 |
| Atrial fibrillationCardiac disorders | 2/617 |
| GastritisGastrointestinal disorders | 2/617 |
| FallInjury, poisoning and procedural complications | 2/617 |
| HyponatraemiaMetabolism and nutrition disorders | 2/617 |
| Spinal column stenosisMusculoskeletal and connective tissue disorders | 2/617 |
| Spinal osteoarthritisMusculoskeletal and connective tissue disorders | 2/617 |
| Atrioventricular block completeCardiac disorders | 1/617 |
| Sick sinus syndromeCardiac disorders | 1/617 |
| Sinus bradycardiaCardiac disorders | 1/617 |
| Event | IPX066 |
|---|---|
| InsomniaPsychiatric disorders | 36/617 |
| DyskinesiaNervous system disorders | 34/617 |
| FallInjury, poisoning and procedural complications | 33/617 |
| NauseaGastrointestinal disorders | 32/617 |
All enrolled subjects
| Age, Continuous(years) | IPX066 |
|---|---|
| Mean | 64.1 ± 9.23 |
| Sex: Female, Male(Participants) | IPX066 |
|---|---|
| Female | 234 |
| Male | 383 |
| Ethnicity (NIH/OMB)(Participants) | IPX066 |
|---|---|
| Hispanic or Latino | 20 |
| Not Hispanic or Latino | 582 |
| Unknown or Not Reported | 15 |
| Race/Ethnicity, Customized(participants) | IPX066 |
|---|---|
| White | 608 |
| Black or African American | 3 |
| Asian | 3 |
| Other | 3 |
| Region of Enrollment(participants) | IPX066 |
|---|---|
| Canada | 48 |
| Latvia | 2 |
| Romania | 43 |
| United States | 260 |
| Ukraine | 165 |
| Poland | 50 |
| Lithuania | 18 |
| Germany | 19 |
| Estonia | 3 |
| Spain | 9 |
Plan to share: No
No publications or documents are linked to this record.
The record gives a start of Mar 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 4 years 5 months after primary completion. A results delay was requested in Sep 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.